Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of adjuvanted cell-derived A/H1N1 influenza vaccine in healthy Japanese pediatric subjects
jRCT2080221032Phase 3
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of adjuvanted cell-derived inactivated A/H1N1 influenza vaccine in influenza A virus infection (H1N1), sponsored by Novartis.
02
Drugs
adjuvanted cell-derived inactivated A/H1N1 influenza vaccine
03
Conditions
influenza A virus infection (H1N1)
Beyond the preview
Go deeper on jRCT2080221032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221032.